A Phase 1 interventional study of Harmine Hydrochloride Capsules in Diabetes Mellitus, sponsored by James Murrough. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-16.
Sponsored by James Murrough · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,023 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.
Among the 3,023 studies in Diabetes Mellitus with a site in United States, this one is the 1,897th largest by enrollment of the 2,502 interventional ones that give a count, is one of 92 that started in 2022, is one of 204 in phase 1, and was the 2,640th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →289 of the 3,023 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
Wayne State University · Sites in United States
Ages 16–20
Mayo Clinic · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,023 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 262 · Phase 2 371 · Phase 3 340 · Phase 4 215
First in 1976; this study’s year is marked. 92 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 82 across the 2,502 interventional studies, 159 across the 499 observational. Of the 2,399 that completed or were terminated, 991 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
852 of 3,023 have an industry lead sponsor. The 10 most frequent:
James Murrough is the lead sponsor of 9 studies on the registry; none are open to participants now.
James Murrough has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
139 of the studies in Diabetes Mellitus with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03982693Phase 3Mt. Sinai Medical Center, MiamiTrial to Assess Chelation Therapy in Critical Limb Ischemia | 2026-12 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07556354University of Alabama at BirminghamEmpowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 3,023 studies in Diabetes Mellitus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine.
The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine. Harmine will be administered in an open-label, dose escalation design that will use the continual reassessment method to inform the next dose to test in a subject. There will be a total of seven possible doses that include 100 mg, 200 mg, 300 mg, 500 mg, 700 mg, 900 mg and 1200 mg. Each study subject will receive a single oral dose of harmine in this single ascending dose design. On the treatment day, subjects will undergo continuous medical monitoring. All adverse events will be documented and events that qualify as dose limiting toxicities (DLTs) will be used to inform dosing for the subsequent subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There will be a total of seven possible doses that include 100 mg, 200 mg, 300 mg, 500 mg, 700 mg, 900 mg and 1200 mg. Each study subject will receive a single oral dose of harmine in this single ascending dose design.
Drug: Harmine Hydrochloride Capsules
capsules taken orally
Number of Participants With Dose Limiting Toxicity (DLT)
DLT which is defined if have any one of the following: Patient Rated Inventory of Side Effects (PRISE): 0-51, higher scores indicate more adverse events observed Brief Psychiatric Rating Scale (BPRS): 4 - 28, higher scores indicate more symptoms of psychosis Vitals: blood pressure and heart rate will all be measured - anything outside of the following ranges will be noted: * Symptomatic hypotension, or \> 20% decrease in systolic blood pressure (SBP) from pre-dosing and an absolute SBP \< 90; or * Symptomatic hypertension, or \> 20% increase in SBP or diastolic blood pressure (DBP) from predosing and absolute SBP \> 170 or DBP \> 95; * New onset tachycardia (heart rate \>100 bpm) and \>20% increase from pre-dosing; or symptomatic bradycardia (heart rate \<60 bpm) and \> 20% decrease from pre-dosing. * Signs and symptoms of cardiac ischemia, defined by acute ischemic changes on ECG with or without concomitant symptoms
Time frame: 24 hours
Maximum Tolerated Dose (MTD) of Oral Harmine HCl Based on Dose Limiting Toxicity (DLT)
The MTD was determined to be between 100 and 200mg and is weight-based.
Time frame: 24 hours
Visual Analog Scale (VAS) - Nausea
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly
Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Visual Analog Scale (VAS) - Hunger
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.
Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Visual Analog Scale (VAS) - Feeling High/Intoxicated
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly
Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Visual Analog Scale (VAS) - Drowsiness
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly
Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Visual Analog Scale (VAS) - Anxiety
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly
Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Visual Analog Scale (VAS) - Depressed Mood
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.
Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Visual Analog Scale (VAS) - Happy Mood
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly
Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Visual Analog Scale (VAS) - Excitement
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.
Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Visual Analog Scale (VAS) - Feeling of Control
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.
Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Visual Analog Scale (VAS) - Vividness of Image
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.
Time frame: baseline, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 8, and 24 hours
Profile of Mood States Bipolar Scale (POMS-Bi): Composed-Anxious Scale
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
Time frame: Baseline, 2, 6, 7, 8, and 24 hours
Profile of Mood States Bipolar Scale (POMS-Bi): Agreeable-Hostile Scale
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
Time frame: Baseline, 2, 6, 7, 8, and 24 hours
Profile of Mood States Bipolar Scale (POMS-Bi): Elated-Depression Scale
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
Time frame: Baseline, 2, 6, 7, 8, and 24 hours
Profile of Mood States Bipolar Scale (POMS-Bi): Confident-Unsure Scale
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
Time frame: Baseline, 2, 6, 7, 8, and 24 hours
Profile of Mood States Bipolar Scale (POMS-Bi): Energetic-Tired Scale
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
Time frame: Baseline, 2, 6, 7, 8, and 24 hours
Profile of Mood States Bipolar Scale (POMS-Bi): Clearheaded-Confused Scale
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
Time frame: Baseline, 2, 6, 7, 8, and 24 hours
Perceived Stress Scale (PSS)
The PSS is a 10-item self-report scale that measures the perception of stress. Each item is rated on a scale from 0-4. Full scale from 0-40, with higher score indicating more perceived stress
Time frame: 24 hours
Patient Rated Inventory of Side Effects (PRISE)
The PRISE is a self-report Adverse Event (AE) Checklist used to qualify side effects by identifying and evaluating the tolerability of each symptom. Only new onset or worsening symptoms were included. Participants could report more than one AE.
Time frame: 24 hours
Brief Psychiatric Rating Scale (BPRS)
The BPRS is a 16-item clinician- administered scale that captures acute behavioral changes throughout treatment. Each item is rated on a scale from 1-7. Full scale from 16-112 with higher score indicating more worse health outcomes.
Time frame: Baseline, 2, 6, 7, 8, and 24 hours
Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a clinician-administered suicidal ideation and behavior rating scale used to evaluate suicide risk. Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation).
Time frame: 24 hours
Between September 2022, and June 2023, a total of 34 participants signed consent with 7 failed screening. 27 were enrolled
| Milestone | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride 300mg | Harmine Hydrochloride 500mg |
|---|---|---|---|---|
| Started | 10 | 12 | 4 | 1 |
| Completed | 10 | 10 | 4 | 1 |
| Not completed | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 0 |
DLT which is defined if have any one of the following: Patient Rated Inventory of Side Effects (PRISE): 0-51, higher scores indicate more adverse events observed Brief Psychiatric Rating Scale (BPRS): 4 - 28, higher scores indicate more symptoms of psychosis Vitals: blood pressure and heart rate will all be measured - anything outside of the following ranges will be noted: * Symptomatic hypotension, or \> 20% decrease in systolic blood pressure (SBP) from pre-dosing and an absolute SBP \< 90; or * Symptomatic hypertension, or \> 20% increase in SBP or diastolic blood pressure (DBP) from predosing and absolute SBP \> 170 or DBP \> 95; * New onset tachycardia (heart rate \>100 bpm) and \>20% increase from pre-dosing; or symptomatic bradycardia (heart rate \<60 bpm) and \> 20% decrease from pre-dosing. * Signs and symptoms of cardiac ischemia, defined by acute ischemic changes on ECG with or without concomitant symptoms
| Participants | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride 300mg | Harmine Hydrochloride 500mg |
|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicity (DLT) | 0 | 6 | 4 | 1 |
The MTD was determined to be between 100 and 200mg and is weight-based.
| mg/kg | Harmine Hydrochloride |
|---|---|
| Maximum Tolerated Dose (MTD) of Oral Harmine HCl Based on Dose Limiting Toxicity (DLT) | 2.7 |
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| baseline | 0.13 (0 to 10) | 0.33 (0 to 10) | 0.10 (0 to 10) |
| 0.5 hours | 0.71 (0 to 10) | 0.80 (0 to 10) | 0.12 (0 to 10) |
| 1 hour | 0.39 (0 to 10) | 2.40 (0 to 10) | 2.30 (0 to 10) |
| 1.5 hours | 0.44 (0 to 10) | 2.25 (0 to 10) | 2.82 (0 to 10) |
| 2 hours | 0.69 (0 to 10) | 1.78 (0 to 10) | 2.22 (0 to 10) |
| 3 hours | 0.25 (0 to 10) | 0.93 (0 to 10) | 1.04 (0 to 10) |
| 4 hours | 0.37 (0 to 10) | 0.48 (0 to 10) | 0.94 (0 to 10) |
| 5 hours | 0.23 (0 to 10) | 0.46 (0 to 10) | 0.60 (0 to 10) |
| 6 hours | 0.24 (0 to 10) | 0.29 (0 to 10) | 0.16 (0 to 10) |
| 7 hours | 0.28 (0 to 10) | 0.65 (0 to 10) | 0.14 (0 to 10) |
| 8 hours | 0.23 (0 to 10) | 0.39 (0 to 10) | 0.16 (0 to 10) |
| 24 hours | 0.25 (0 to 10) | 0.32 (0 to 10) | 0.08 (0 to 10) |
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| baseline | 2.31 (0 to 10) | 3.91 (0 to 10) | 2.96 (0 to 10) |
| 0.5 hours | 4.10 (0 to 10) | 3.40 (0 to 10) | 4.32 (0 to 10) |
| 1 hour | 2.64 (0 to 10) | 3.58 (0 to 10) | 4.66 (0 to 10) |
| 1.5 hours | 5.39 (0 to 10) | 4.26 (0 to 10) | 5.88 (0 to 10) |
| 2 hours | 5.38 (0 to 10) | 4.74 (0 to 10) | 4.94 (0 to 10) |
| 3 hours | 4.68 (0 to 10) | 4.65 (0 to 10) | 5.36 (0 to 10) |
| 4 hours | 4.14 (0 to 10) | 4.78 (0 to 10) | 6.16 (0 to 10) |
| 5 hours | 2.56 (0 to 10) | 1.85 (0 to 10) | 2.54 (0 to 10) |
| 6 hours | 2.98 (0 to 10) | 2.02 (0 to 10) | 3.86 (0 to 10) |
| 7 hours | 3.66 (0 to 10) | 3.35 (0 to 10) | 4.02 (0 to 10) |
| 8 hours | 2.87 (0 to 10) | 4.29 (0 to 10) | 4.30 (0 to 10) |
| 24 hours | 3.95 (0 to 10) | 3.51 (0 to 10) | 4.74 (0 to 10) |
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| baseline | 0.80 (0 to 10) | 0.44 (0 to 10) | 0.12 (0 to 10) |
| 0.5 hours | 0.77 (0 to 10) | 0.88 (0 to 10) | 3.52 (0 to 10) |
| 1 hour | 1.09 (0 to 10) | 2.23 (0 to 10) | 4.52 (0 to 10) |
| 1.5 hours | 1.29 (0 to 10) | 2.43 (0 to 10) | 3.1 (0 to 10) |
| 2 hours | 0.18 (0 to 10) | 2.27 (0 to 10) | 2.74 (0 to 10) |
| 3 hours | 0.54 (0 to 10) | 0.62 (0 to 10) | 0.16 (0 to 10) |
| 4 hours | 0.84 (0 to 10) | 0.57 (0 to 10) | 0.22 (0 to 10) |
| 5 hours | 0.40 (0 to 10) | 0.49 (0 to 10) | 0.22 (0 to 10) |
| 6 hours | 0.53 (0 to 10) | 0.66 (0 to 10) | 0.18 (0 to 10) |
| 7 hours | 0.76 (0 to 10) | 0.65 (0 to 10) | 0.12 (0 to 10) |
| 8 hours | 0.56 (0 to 10) | 0.86 (0 to 10) | 0.14 (0 to 10) |
| 24 hours | 0.62 (0 to 10) | 0.54 (0 to 10) | 0.12 (0 to 10) |
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| baseline | 1.43 (0 to 10) | 2.14 (0 to 10) | 2.46 (0 to 10) |
| 0.5 hours | 1.98 (0 to 10) | 3.04 (0 to 10) | 3.10 (0 to 10) |
| 1 hour | 2.54 (0 to 10) | 3.02 (0 to 10) | 3.60 (0 to 10) |
| 1.5 hours | 2.58 (0 to 10) | 3.96 (0 to 10) | 4.50 (0 to 10) |
| 2 hours | 1.97 (0 to 10) | 3.86 (0 to 10) | 4.72 (0 to 10) |
| 3 hours | 1.58 (0 to 10) | 3.24 (0 to 10) | 3.46 (0 to 10) |
| 4 hours | 2.29 (0 to 10) | 2.56 (0 to 10) | 3.32 (0 to 10) |
| 5 hours | 1.10 (0 to 10) | 1.86 (0 to 10) | 2.50 (0 to 10) |
| 6 hours | 1.86 (0 to 10) | 1.73 (0 to 10) | 0.96 (0 to 10) |
| 7 hours | 1.75 (0 to 10) | 1.77 (0 to 10) | 2.92 (0 to 10) |
| 8 hours | 1.43 (0 to 10) | 2.20 (0 to 10) | 2.20 (0 to 10) |
| 24 hours | 1.80 (0 to 10) | 1.00 (0 to 10) | 2.68 (0 to 10) |
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| baseline | 0.38 (0 to 10) | 1.01 (0 to 10) | 0.42 (0 to 10) |
| 0.5 hours | 0.33 (0 to 10) | 0.79 (0 to 10) | 2.58 (0 to 10) |
| 1 hour | 1 (0 to 10) | 1.03 (0 to 10) | 1.56 (0 to 10) |
| 1.5 hours | 0.59 (0 to 10) | 0.76 (0 to 10) | 0.70 (0 to 10) |
| 2 hours | 0.53 (0 to 10) | 0.78 (0 to 10) | 0.22 (0 to 10) |
| 3 hours | 0.42 (0 to 10) | 0.54 (0 to 10) | 0.08 (0 to 10) |
| 4 hours | 0.38 (0 to 10) | 0.55 (0 to 10) | 0.28 (0 to 10) |
| 5 hours | 0.24 (0 to 10) | 0.58 (0 to 10) | 0.26 (0 to 10) |
| 6 hours | 0.28 (0 to 10) | 0.51 (0 to 10) | 0.20 (0 to 10) |
| 7 hours | 0.19 (0 to 10) | 0.53 (0 to 10) | 0.04 (0 to 10) |
| 8 hours | 0.17 (0 to 10) | 0.62 (0 to 10) | 0.12 (0 to 10) |
| 24 hours | 0.31 (0 to 10) | 0.57 (0 to 10) | 0.14 (0 to 10) |
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| baseline | 0.19 (0 to 10) | 0.33 (0 to 10) | 0.38 (0 to 10) |
| 0.5 hours | 1.18 (0 to 10) | 0.41 (0 to 10) | 0.16 (0 to 10) |
| 1 hour | 0.26 (0 to 10) | 0.28 (0 to 10) | 0.46 (0 to 10) |
| 1.5 hours | 0.28 (0 to 10) | 0.44 (0 to 10) | 0.24 (0 to 10) |
| 2 hours | 0.64 (0 to 10) | 0.38 (0 to 10) | 0.10 (0 to 10) |
| 3 hours | 0.22 (0 to 10) | 0.36 (0 to 10) | 0.14 (0 to 10) |
| 4 hours | 0.24 (0 to 10) | 0.38 (0 to 10) | 0.28 (0 to 10) |
| 5 hours | 0.22 (0 to 10) | 0.28 (0 to 10) | 0.84 (0 to 10) |
| 6 hours | 0.20 (0 to 10) | 0.18 (0 to 10) | 0.16 (0 to 10) |
| 7 hours | 0.31 (0 to 10) | 0.29 (0 to 10) | 0.12 (0 to 10) |
| 8 hours | 0.20 (0 to 10) | 0.31 (0 to 10) | 0.16 (0 to 10) |
| 24 hours | 0.20 (0 to 10) | 0.33 (0 to 10) | 0.12 (0 to 10) |
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| baseline | 6.13 (0 to 10) | 5.22 (0 to 10) | 5.60 (0 to 10) |
| 0.5 hours | 5.73 (0 to 10) | 4.28 (0 to 10) | 5.50 (0 to 10) |
| 1 hour | 5.63 (0 to 10) | 4.27 (0 to 10) | 4.80 (0 to 10) |
| 1.5 hours | 4.90 (0 to 10) | 4.45 (0 to 10) | 3.94 (0 to 10) |
| 2 hours | 5.34 (0 to 10) | 3.83 (0 to 10) | 3.72 (0 to 10) |
| 3 hours | 5.43 (0 to 10) | 3.98 (0 to 10) | 4.12 (0 to 10) |
| 4 hours | 5.70 (0 to 10) | 4.50 (0 to 10) | 5.22 (0 to 10) |
| 5 hours | 5.10 (0 to 10) | 4.34 (0 to 10) | 4.20 (0 to 10) |
| 6 hours | 5.07 (0 to 10) | 4.39 (0 to 10) | 5.02 (0 to 10) |
| 7 hours | 5.37 (0 to 10) | 4.17 (0 to 10) | 4.32 (0 to 10) |
| 8 hours | 5.70 (0 to 10) | 4.19 (0 to 10) | 4.36 (0 to 10) |
| 24 hours | 5.84 (0 to 10) | 4.85 (0 to 10) | 4.84 (0 to 10) |
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| baseline | 2.55 (0 to 10) | 2.12 (0 to 10) | 3.90 (0 to 10) |
| 0.5 hours | 2.35 (0 to 10) | 1.44 (0 to 10) | 3.92 (0 to 10) |
| 1 hour | 2.66 (0 to 10) | 2.10 (0 to 10) | 3.46 (0 to 10) |
| 1.5 hours | 1.53 (0 to 10) | 1.89 (0 to 10) | 2.48 (0 to 10) |
| 2 hours | 2.37 (0 to 10) | 2.02 (0 to 10) | 2.92 (0 to 10) |
| 3 hours | 2.50 (0 to 10) | 1.65 (0 to 10) | 3.16 (0 to 10) |
| 4 hours | 2.49 (0 to 10) | 2.29 (0 to 10) | 2.76 (0 to 10) |
| 5 hours | 2.25 (0 to 10) | 2.17 (0 to 10) | 2.16 (0 to 10) |
| 6 hours | 3.21 (0 to 10) | 1.42 (0 to 10) | 2.36 (0 to 10) |
| 7 hours | 2.54 (0 to 10) | 1.02 (0 to 10) | 2.68 (0 to 10) |
| 8 hours | 2.58 (0 to 10) | 1.39 (0 to 10) | 2.70 (0 to 10) |
| 24 hours | 4.01 (0 to 10) | 2.35 (0 to 10) | 2.98 (0 to 10) |
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| baseline | 4.00 (0 to 10) | 3.27 (0 to 10) | 3.24 (0 to 10) |
| 0.5 hours | 3.84 (0 to 10) | 2.00 (0 to 10) | 5.46 (0 to 10) |
| 1 hour | 3.14 (0 to 10) | 3.81 (0 to 10) | 3.96 (0 to 10) |
| 1.5 hours | 3.39 (0 to 10) | 1.91 (0 to 10) | 4.04 (0 to 10) |
| 2 hours | 3.48 (0 to 10) | 3.07 (0 to 10) | 4.24 (0 to 10) |
| 3 hours | 4.13 (0 to 10) | 2.17 (0 to 10) | 3.56 (0 to 10) |
| 4 hours | 4.22 (0 to 10) | 2.87 (0 to 10) | 3.56 (0 to 10) |
| 5 hours | 3.07 (0 to 10) | 2.51 (0 to 10) | 3.48 (0 to 10) |
| 6 hours | 3.75 (0 to 10) | 2.14 (0 to 10) | 4.44 (0 to 10) |
| 7 hours | 3.76 (0 to 10) | 1.80 (0 to 10) | 4.50 (0 to 10) |
| 8 hours | 3.83 (0 to 10) | 2.11 (0 to 10) | 4.56 (0 to 10) |
| 24 hours | 3.94 (0 to 10) | 3.52 (0 to 10) | 5.30 (0 to 10) |
Visual Analog Scale (VAS) to characterize psychoactive effects of harmine in healthy adults. Full scale from 0-10, with higher scores indicating subjective states are experienced more strongly.
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| baseline | 5.34 (0 to 10) | 2.99 (0 to 10) | 2.10 (0 to 10) |
| 0.5 hours | 5.03 (0 to 10) | 2.42 (0 to 10) | 3.50 (0 to 10) |
| 1 hour | 5.17 (0 to 10) | 2.94 (0 to 10) | 4.24 (0 to 10) |
| 1.5 hours | 5.21 (0 to 10) | 2.75 (0 to 10) | 3.76 (0 to 10) |
| 2 hours | 5.33 (0 to 10) | 2.57 (0 to 10) | 3.24 (0 to 10) |
| 3 hours | 5.82 (0 to 10) | 2.76 (0 to 10) | 2.04 (0 to 10) |
| 4 hours | 5.70 (0 to 10) | 2.61 (0 to 10) | 2.32 (0 to 10) |
| 5 hours | 5.78 (0 to 10) | 2.45 (0 to 10) | 2.02 (0 to 10) |
| 6 hours | 5.72 (0 to 10) | 2.21 (0 to 10) | 2.58 (0 to 10) |
| 7 hours | 5.70 (0 to 10) | 2.17 (0 to 10) | 2.16 (0 to 10) |
| 8 hours | 5.94 (0 to 10) | 2.39 (0 to 10) | 2.50 (0 to 10) |
| 24 hours | 5.91 (0 to 10) | 2.45 (0 to 10) | 2.20 (0 to 10) |
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Baseline | 33.9 (0 to 36) | 29.3 (0 to 36) | 33.6 (0 to 36) |
| 2 hours | 31.7 (0 to 36) | 28.5 (0 to 36) | 29 (0 to 36) |
| 6 hours | 31.9 (0 to 36) | 30.7 (0 to 36) | 33.6 (0 to 36) |
| 7 hours | 33.5 (0 to 36) | 29.1 (0 to 36) | 32.8 (0 to 36) |
| 8 hours | 32.7 (0 to 36) | 29.2 (0 to 36) | 31.4 (0 to 36) |
| 24 hours | 33.1 (0 to 36) | 29.3 (0 to 36) | 33.0 (0 to 36) |
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Baseline | 31.5 (0 to 36) | 28.7 (0 to 36) | 31.6 (0 to 36) |
| 2 hours | 30.0 (0 to 36) | 28.1 (0 to 36) | 29.2 (0 to 36) |
| 6 hours | 31.1 (0 to 36) | 28.1 (0 to 36) | 30.6 (0 to 36) |
| 7 hours | 31.8 (0 to 36) | 27.0 (0 to 36) | 30.6 (0 to 36) |
| 8 hours | 32.2 (0 to 36) | 27.7 (0 to 36) | 30.0 (0 to 36) |
| 24 hours | 33.0 (0 to 36) | 27.6 (0 to 36) | 29.8 (0 to 36) |
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Baseline | 29.1 (0 to 36) | 25.6 (0 to 36) | 27.0 (0 to 36) |
| 2 hours | 28.1 (0 to 36) | 24.6 (0 to 36) | 24.6 (0 to 36) |
| 6 hours | 29.0 (0 to 36) | 25.8 (0 to 36) | 27.2 (0 to 36) |
| 7 hours | 28.9 (0 to 36) | 24.7 (0 to 36) | 25.6 (0 to 36) |
| 8 hours | 29.8 (0 to 36) | 25.0 (0 to 36) | 26.0 (0 to 36) |
| 24 hours | 31.4 (0 to 36) | 25.5 (0 to 36) | 26.0 (0 to 36) |
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Baseline | 27.4 (0 to 36) | 24.3 (0 to 36) | 27.4 (0 to 36) |
| 2 hours | 24.8 (0 to 36) | 22.6 (0 to 36) | 21.6 (0 to 36) |
| 6 hours | 26.5 (0 to 36) | 24.5 (0 to 36) | 22.4 (0 to 36) |
| 7 hours | 27.1 (0 to 36) | 22.9 (0 to 36) | 23.4 (0 to 36) |
| 8 hours | 27.0 (0 to 36) | 23.2 (0 to 36) | 24 (0 to 36) |
| 24 hours | 29.0 (0 to 36) | 24.6 (0 to 36) | 26.0 (0 to 36) |
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Baseline | 24.5 (0 to 36) | 20.9 (0 to 36) | 21.8 (0 to 36) |
| 2 hours | 22.0 (0 to 36) | 14.5 (0 to 36) | 7.2 (0 to 36) |
| 6 hours | 23.1 (0 to 36) | 20.1 (0 to 36) | 19.6 (0 to 36) |
| 7 hours | 23.5 (0 to 36) | 20.2 (0 to 36) | 16.2 (0 to 36) |
| 8 hours | 26.1 (0 to 36) | 20.5 (0 to 36) | 19.4 (0 to 36) |
| 24 hours | 29.3 (0 to 36) | 24.0 (0 to 36) | 20.8 (0 to 36) |
The POMS-Bi is a 72-item psychological self-report rating scale used to assess transient, distinct mood states. It is also a validated instrument for identifying the effects of drug treatments. Items are rated on a four-point scale from 0 "much unlike this" to 3 "much like this." It includes six bipolar scales: composed-anxious, agreeable-hostile, elated-depressed, confident-unsure, energetic-tired, and clearheaded-confused. Each subscale is scored 0-36, with higher scores associated with better mood
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Baseline | 31.1 (0 to 36) | 27.9 (0 to 36) | 31.2 (0 to 36) |
| 2 hours | 29.0 (0 to 36) | 24.7 (0 to 36) | 22.2 (0 to 36) |
| 6 hours | 30.3 (0 to 36) | 27.5 (0 to 36) | 29.6 (0 to 36) |
| 7 hours | 30.6 (0 to 36) | 26.9 (0 to 36) | 27.8 (0 to 36) |
| 8 hours | 31.2 (0 to 36) | 26.6 (0 to 36) | 28.6 (0 to 36) |
| 24 hours | 32.4 (0 to 36) | 28.3 (0 to 36) | 30.0 (0 to 36) |
The PSS is a 10-item self-report scale that measures the perception of stress. Each item is rated on a scale from 0-4. Full scale from 0-40, with higher score indicating more perceived stress
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Baseline | 5.7 (0 to 40) | 7.1 (0 to 40) | 5.8 (0 to 40) |
| 6 hours | 6.8 (0 to 40) | 7.2 (0 to 40) | 4.8 (0 to 40) |
| 7 hours | 6.3 (0 to 40) | 7.8 (0 to 40) | 5.6 (0 to 40) |
| 8 hours | 5.7 (0 to 40) | 8.5 (0 to 40) | 5.2 (0 to 40) |
| 24 hours | 6.2 (0 to 40) | 7.8 (0 to 40) | 6.6 (0 to 40) |
The PRISE is a self-report Adverse Event (AE) Checklist used to qualify side effects by identifying and evaluating the tolerability of each symptom. Only new onset or worsening symptoms were included. Participants could report more than one AE.
| Participants | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Decreased energy | 3 | 8 | 5 |
| Fatigue | 4 | 9 | 3 |
| Dizziness | 3 | 5 | 5 |
| Nausea/vomiting | 0 | 5 | 5 |
| Dizziness on standing | 1 | 3 | 5 |
| Poor concentration | 2 | 3 | 3 |
| Headache | 2 | 4 | 1 |
| Poor coordination | 1 | 3 | 2 |
| Anxiety | 1 | 1 | 2 |
| Restlessness | 2 | 1 | 1 |
| Palpitations | 1 | 2 | 1 |
| Dry mouth | 2 | 1 | 1 |
| Sleeping too much | 0 | 2 | 1 |
| Tremors | 0 | 3 | 0 |
| Blurred vision | 0 | 3 | 0 |
| Ringing in ears | 0 | 0 | 2 |
| Increased perspiration | 0 | 1 | 1 |
| General malaise | 0 | 1 | 0 |
| Difficulty sleeping | 0 | 1 | 0 |
| Constipation | 1 | 0 | 0 |
The BPRS is a 16-item clinician- administered scale that captures acute behavioral changes throughout treatment. Each item is rated on a scale from 1-7. Full scale from 16-112 with higher score indicating more worse health outcomes.
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Baseline | 16 (16 to 112) | 16.1 (16 to 112) | 16 (16 to 112) |
| 2 hours | 16 (16 to 112) | 16.3 (16 to 112) | 16 (16 to 112) |
| 6 hours | 16 (16 to 112) | 16 (16 to 112) | 16 (16 to 112) |
| 7 hours | 16 (16 to 112) | 16 (16 to 112) | 16 (16 to 112) |
| 8 hours | 16 (16 to 112) | 16 (16 to 112) | 16 (16 to 112) |
| 24 hours | 16 (16 to 112) | 16 (16 to 112) | 16 (16 to 112) |
The C-SSRS is a clinician-administered suicidal ideation and behavior rating scale used to evaluate suicide risk. Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation).
| score on a scale | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Columbia Suicide Severity Rating Scale (C-SSRS) | 0 (0 to 9) | 0 (0 to 9) | 0 (0 to 9) |
Collected over 24 hours. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Harmine Hydrochloride 100mg | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Harmine Hydrochloride 200mg | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Harmine Hydrochloride >200mg | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Event | Harmine Hydrochloride 100mg | Harmine Hydrochloride 200mg | Harmine Hydrochloride >200mg |
|---|---|---|---|
| Vomiting/emesisGastrointestinal disorders | 0/10 | 3/10 | 5/5 |
| Impaired concentration/confusionNervous system disorders | 1/10 | 3/10 | 0/5 |
| DrowsinessNervous system disorders | 0/10 | 3/10 | 0/5 |
| DizzinessNervous system disorders | 2/10 | 1/10 | 1/5 |
| Auditory hallucinationNervous system disorders | 0/10 | 0/10 | 1/5 |
| GiddinessNervous system disorders | 0/10 | 0/10 | 1/5 |
| HypotensionCardiac disorders | 0/10 | 0/10 | 1/5 |
| VasovagalNervous system disorders | 0/10 | 0/10 | 1/5 |
| Visual illusionNervous system disorders | 0/10 | 1/10 | 0/5 |
| TinglingNervous system disorders | 0/10 | 1/10 | 0/5 |
Harmine 300mg and 500mg combined to maintain confidentiality of one participant in 500mg arm
| Age, Continuous(years) | Harmine Dose 100 mg | Harmine 200 mg | Harmine >200mg | Total |
|---|---|---|---|---|
| Median | 28.9 ± 6.6 | 31.1 ± 7.3 | 29.4 ± 3.9 | 29.9 ± 6.3 |
| Sex: Female, Male(Participants) | Harmine Dose 100 mg | Harmine 200 mg | Harmine >200mg | Total |
|---|---|---|---|---|
| Female | 5 | 5 | 2 | 12 |
| Male | 5 | 5 | 3 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Harmine Dose 100 mg | Harmine 200 mg | Harmine >200mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 2 | 6 |
| Not Hispanic or Latino | 7 | 8 | 3 | 18 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Harmine Dose 100 mg | Harmine 200 mg | Harmine >200mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 2 | 5 | 0 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 3 |
| White | 4 | 5 | 3 | 12 |
| More than one race | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Weight(kg) | Harmine Dose 100 mg | Harmine 200 mg | Harmine >200mg | Total |
|---|---|---|---|---|
| Mean | 66.2 ± 10.8 | 69.7 ± 14.9 | 76 ± 22.6 | 69.6 ± 15 |
| Body mass index(kg/m^2) | Harmine Dose 100 mg | Harmine 200 mg | Harmine >200mg | Total |
|---|---|---|---|---|
| Mean | 24.8 ± 2.7 | 24.5 ± 3.0 | 25.2 ± 4.0 | 24.8 ± 3.0 |
| Education level(Participants) | Harmine Dose 100 mg | Harmine 200 mg | Harmine >200mg | Total |
|---|---|---|---|---|
| Some college | 1 | 0 | 0 | 1 |
| Graduated 2-year college/trade school | 0 | 1 | 0 | 1 |
| Graduated 4-year college | 2 | 0 | 2 | 4 |
| Some graduate/professional school | 3 | 4 | 3 | 10 |
| Completed graduate/professional school | 4 | 5 | 0 | 9 |
| Marital status(Participants) | Harmine Dose 100 mg | Harmine 200 mg | Harmine >200mg | Total |
|---|---|---|---|---|
| Married/living with someone as if married | 4 | 4 | 1 | 9 |
| Never married | 6 | 6 | 4 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — As of now the study team is not plan on sharing IPD as that would not align with the approved management plan.
Ran from Sep 2022 to primary completion in Jun 2023, 9 months.
Results were first posted in Jan 2025, 1 year 6 months after primary completion.
Of 76 non-industry phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 55. This study's 9 months is below that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
James Murrough